valsartan has been researched along with Alloxan Diabetes in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.06) | 18.2507 |
| 2000's | 31 (39.24) | 29.6817 |
| 2010's | 34 (43.04) | 24.3611 |
| 2020's | 10 (12.66) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, L; Cao, Z; Guo, Q; Huang, Q; Li, W; Liu, X; Zeng, R | 1 |
| Ahmed, MM; Al-Hoshani, A; Al-Rejaie, SS; Alotaibi, MM; Belali, OM; Belali, TM; Mohany, M | 1 |
| Asghari, AA; Mahmoudabady, M; Niazmand, S; Shabab, S | 1 |
| Barrow, BM; Castillo, JJ; Cronic, L; Esser, N; Hackney, DJ; Hogan, MF; Hull, RL; Mongovin, SM; Schmidt, C; Templin, AT; Zraika, S | 1 |
| Abdo, VB; Ashour, RH; Elshenawy, DSA; Ramadan, NM | 1 |
| Clahsen-van Groningen, MC; Cruz-López, EO; Danser, AHJ; Domenig, O; Foster, D; Garrelds, IM; Kasper, A; Nioi, P; Poglitsch, M; Ren, L; Rooney, T; Uijl, E; van Veghel, R; Zlatev, I | 1 |
| Asghari, AA; Hosseini, SJ; Mahmoudabady, M; Mousavi Emadi, Z; Salmani, H | 1 |
| Chen, Y; Han, X; Liu, J; Ma, Y; Xie, D; Xu, H | 1 |
| Chen, H; Liu, F; Ma, Q; Yang, H | 1 |
| Keshawy, MM; Makary, S; Tawfik, MK | 1 |
| Abadir, P; Ansari, A; Berger, A; Beselman, A; Budman, J; Faghih, M; Fedarko, N; Harmon, J; Hosseini, S; Inagami, T; Keenahan, K; Lay, F; Marti, G; Rini, D; Smith, B; Tian, J; Vuong, D; Walston, J | 1 |
| Li, H; Qin, X; Shan, M; Tie, Y; Yu, F; Zhai, C; Zhang, C; Zhang, Y | 1 |
| Ahmad, SNS; Argani, H; Aslani, S; Ghorbani Haghjo, A; Jigheh, ZA; Mesgari Abbasi, M; Panah, F; Rashedi, J; Roshangar, L; Sanajou, D | 1 |
| Bafor, EE; Bolanle, IO; Omogbai, EKI | 1 |
| Bao, SL; Liu, WT; Pan, J; Sun, HX | 1 |
| Ahmad, SNS; Argani, H; Ashrafi-Jigheh, Z; Asiaee, F; Aslani, S; Bahrambeigi, S; Ghorbani Haghjo, A; Rashedi, J; Rashtchizadeh, N; Roshangar, L; Sanajou, D | 1 |
| Ge, Q; Hu, ZY; Ren, XM; Ye, P; Zhao, L | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Shi, FH; Wu, Y; Zhang, YM | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Ding, MJ; Liu, GL; Zhang, YM | 1 |
| El-Maraghy, SA; Motawi, TK; Senousy, MA | 1 |
| Wei, JR; Zhang, YL | 1 |
| Guan, G; Li, P; Lv, W; Qi, D; Wang, J; Zhang, Y | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Baker, KM; Chandel, N; Kumar, R; Seqqat, R; Thomas, CM; Yong, QC | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Guo, T; Hao, P; Kong, J; Li, D; Meng, X; Yang, J; Zhang, C; Zhang, K; Zhang, M; Zhang, Y | 1 |
| Chang, KC; Ha, YM; Kang, YJ; Kim, HJ; Park, EJ; Park, SW | 1 |
| Bi, X; Li, S; Ma, X; Miao, Y; Su, G; Sun, H; Zhang, W; Zhang, Y; Zhao, Y; Zhong, M | 1 |
| Dai, HY; Guan, J; Jiang, CQ; Liu, WQ; Shi, Y; Tan, XY; Xing, MQ | 1 |
| Arimura, T; Goto, M; Imaizumi, S; Iwata, A; Kuwano, T; Matsuo, Y; Miura, S; Saku, K; Suematsu, Y; Yahiro, E | 1 |
| Cao, Y; Duan, H; Gao, F; Liu, Q; Liu, S; Yao, M | 1 |
| Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; Danser, AH; de Vries, R; Friesema, EC; Garrelds, IM; Hoorn, EJ; Leijten, FP; Roksnoer, LC; van Gool, JM; van Veghel, R | 1 |
| Chen, ZJ; Fu, P; Huang, SM; Tang, WX; Tao, Y | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, JL; Zhang, Y | 1 |
| Abadir, PM; Abdel-Rahman, EM; Siragy, HM | 1 |
| Lu, J; Sun, L; Yu, XJ; Zang, WJ; Zhang, CH | 1 |
| Chen, FM; Fu, GS; Wang, H; Wang, YJ | 1 |
| Cheng, S; Li, H; Li, J; Li, X; Qi, C; Xu, G; Yuan, L | 1 |
| Li, X; Qi, CJ; Xu, GL; Yuan, L | 1 |
| Kamal, F; Morioka, T; Oite, T; Piao, H; Yanakieva-Georgieva, N | 1 |
| Huang, J; Matavelli, LC; Siragy, HM | 1 |
| Dong, Z; Ge, Z; Geng, J; Kang, W; Liu, G; Sun, Y; Wu, T; Zhang, Y | 1 |
| Birnbaum, Y; Castillo, AC; Perez-Polo, JR; Qian, J; Ye, Y | 1 |
| Chen, H; Li, H; Liu, Z; Tang, L; Yang, B; Yi, R | 1 |
| Fan, J; Hoffman, MR; Qin, Y; Ren, H; Xu, G; Zhang, M | 1 |
| Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
| Aksak, S; Albayrak, A; Albayrak, F; Gundogdu, C; Halici, Z; Karakus, E; Kiki, I; Ozturk, B; Polat, B; Sipal, S | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 1 |
| Baker, KM; Chandel, N; Feldman, DL; Kumar, R; Seqqat, R; Thomas, CM; Yong, QC | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H | 1 |
| Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Wong, KL; Yang, TL | 1 |
| Abadir, P; Awad, A; Siragy, HM; Webb, R | 1 |
| Awad, AS; Carey, RM; Siragy, HM; Webb, RL | 2 |
| Alderson, NL; Cooper, ME; Forbes, JM; Thomas, MC; Thorpe, SR | 1 |
| Xie, XW; Zhao, P | 1 |
| Chu, GL; Ding, GH; Gao, P; Jia, RH; Liu, HY; Song, EF; Yang, DP | 1 |
| Siragy, HM; Xue, C | 1 |
| Ma, X; Miao, Y; Sun, H; Tang, MX; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Gong, HP; Li, L; Ma, X; Miao, Y; Sun, H; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Yang, TL | 1 |
| Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL | 1 |
| Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL | 1 |
| Ma, X; Miao, Y; Qi, TG; Sun, H; Zhang, W; Zhong, M | 1 |
| Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
| Bai, A; Bianchi, R; Cuccovillo, I; De Angelis, N; Fiordaliso, F; Latini, R; Masson, S; Razzetti, R; Salio, M; Serra, DM | 1 |
| Huang, J; Siragy, HM | 1 |
| Imamura, Y; Ishida, S; Kurihara, T; Nagai, N; Noda, K; Oike, Y; Okano, H; Ozawa, Y; Shinoda, K; Tsubota, K | 1 |
| Cooper, ME; Komers, R | 1 |
| Cao, Z; Cooper, ME; Hulthén, UL; Johnston, CI; Rumble, JR | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Hulthen, UL; Youssef, S | 1 |
| Cooper, ME; Gibbs, NJ; Kelly, DJ; Skinner, SL; Wilkinson-Berka, JL | 1 |
| Allen, TJ; Bertram, JF; Cooper, ME; Gilbert, RE; Hulthen, UL; Kelly, DJ; Mifsud, SA; Wilkinson-Berka, JL | 1 |
| Shimoni, Y | 1 |
| Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL | 1 |
| Lin, S; Wen, H | 1 |
| Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I | 1 |
1 review(s) available for valsartan and Alloxan Diabetes
| Article | Year |
|---|---|
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Glycation End Products, Advanced; Tetrazoles; Valine; Valsartan | 2004 |
78 other study(ies) available for valsartan and Alloxan Diabetes
| Article | Year |
|---|---|
Valsartan alleviates the blood-brain barrier dysfunction in db/db diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells; Inflammation; Male; Mice; Valsartan; Vascular Diseases | 2021 |
LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-κB and PERK/CHOP Signaling Pathways.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diet, High-Fat; Drug Combinations; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glycation End Products, Advanced; Inflammation; Male; Myocardium; NF-kappa B; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Signal Transduction; Streptozocin; Transcription Factor CHOP; Valsartan | 2022 |
Anti-inflammatory, anti-oxidant and anti-apoptotic effects of olive leaf extract in cardiac tissue of diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Experimental; Metformin; Olea; Oxidative Stress; Plant Extracts; Rats; Rats, Wistar; Sulfhydryl Compounds; Superoxide Dismutase; Valsartan | 2022 |
Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Insulin Resistance; Insulins; Mice; Mice, Inbred C57BL; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2022 |
Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Glycogen; Heart Failure; Hyperglycemia; Mice; Rats; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Blood pressure-independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes.
Topics: Albuminuria; Angiotensin II; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Humans; Hypertension; Kidney Diseases; Liver; Rats; Renin; Renin-Angiotensin System; RNA, Small Interfering; Valsartan | 2023 |
Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes.
Topics: Animals; Body Weight; Cardiomegaly; Diabetes Mellitus, Experimental; Fibrosis; Rats; Valsartan | 2022 |
Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
Topics: Angiopoietin-Like Protein 3; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Failure, Chronic; Mice; Podocytes; Reactive Oxygen Species; Streptozocin; Valsartan | 2023 |
Up-regulation of matrix metalloproteinases-9 in the kidneys of diabetic rats and the association with neutrophil gelatinase-associated lipocalin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Tubules, Proximal; Lipocalin-2; Male; Matrix Metalloproteinase 9; Random Allocation; Rats; Rats, Sprague-Dawley; Up-Regulation; Valsartan | 2021 |
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression.
Topics: Angiopoietin-Like Protein 2; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Expression; Kidney; Male; NF-kappa B; Protective Agents; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 2; RNA, Messenger; Streptozocin; Toll-Like Receptor 4; Treatment Outcome; Valsartan | 2021 |
Topical Reformulation of Valsartan for Treatment of Chronic Diabetic Wounds.
Topics: Administration, Cutaneous; Alloxan; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chronic Disease; Diabetes Mellitus, Experimental; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Angiotensin, Type 1; Skin; Swine; Swine, Miniature; Time Factors; Treatment Outcome; Valsartan; Wound Healing; Wounds and Injuries | 2018 |
CCAAT/enhancer-binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin-converting enzyme-2 expression in diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibroblasts; Gene Expression Regulation; Glucose; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Peptidyl-Dipeptidase A; Primary Cell Culture; Protein Binding; Rats; RNA, Small Interfering; Streptozocin; Valsartan | 2018 |
FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Glomerular Filtration Barrier; Injections, Intraperitoneal; Macrophages; Male; Microscopy, Fluorescence; Phosphorylation; Podocytes; Protein Processing, Post-Translational; Random Allocation; Rats, Wistar; Receptor for Advanced Glycation End Products; Renal Insufficiency; Transcription Factor RelA; Valsartan | 2018 |
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Drug Interactions; Glyburide; Hypoglycemic Agents; Male; Rats, Wistar; Risk Assessment; Streptozocin; Time Factors; Valsartan | 2018 |
Valsartan improves cardiac function in mice with diabetes mellitus by CaMKII/AngII.
Topics: Animals; Calcium; Calcium-Binding Proteins; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Diabetes Mellitus, Experimental; Diastole; Echocardiography; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Phosphorylation; Ryanodine Receptor Calcium Release Channel; Systole; Valsartan | 2018 |
Reduction of renal tubular injury with a RAGE inhibitor FPS-ZM1, valsartan and their combination in streptozotocin-induced diabetes in the rat.
Topics: Animals; Benzamides; Collagen; Diabetes Mellitus, Experimental; Drug Interactions; Epithelial Cells; Fibrosis; Glycation End Products, Advanced; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Wistar; Valsartan | 2019 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apoptosis; Biphenyl Compounds; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Inflammation; Male; Mice; Muscle Proteins; Myocardium; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Tetrazoles; Valsartan | 2019 |
Hepatosteatosis and hepatic insulin resistance are blunted by argirein, an anti-inflammatory agent, through normalizing endoplasmic reticulum stress and apoptosis in diabetic liver.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Apoptosis; Arginine; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug Combinations; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glucose; Glucose Transporter Type 4; Glutathione Peroxidase; Glycogen; Heat-Shock Proteins; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Leptin; Tetrazoles; Transcription Factor CHOP; Valine; Valsartan | 2013 |
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Combinations; Endoplasmic Reticulum Stress; Hypogonadism; I-kappa B Proteins; Male; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Streptozocin; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Gene Expression Regulation, Enzymologic; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model.
Topics: Animals; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Male; Myocardium; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Tetrazoles; Tyrosine; Valine; Valsartan | 2013 |
Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Diabetes Mellitus, Experimental; Kidney; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan; WT1 Proteins | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Down-Regulation; Fumarates; Kallikreins; Kininogens; Kinins; Mice; Mice, Knockout; Myocytes, Cardiac; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Ultrasonography; Valine; Valsartan | 2013 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Male; Mesangial Cells; Oxidative Stress; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Valsartan; Vascular Endothelial Growth Factor A | 2015 |
Valsartan independent of AT₁ receptor inhibits tissue factor, TLR-2 and -4 expression by regulation of Egr-1 through activation of AMPK in diabetic conditions.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cells, Cultured; Chromatin Immunoprecipitation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Early Growth Response Protein 1; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucose Tolerance Test; Humans; Male; Mice; Mice, Inbred C57BL; Monocytes; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Tetrazoles; Thromboplastin; Toll-Like Receptor 2; Toll-Like Receptor 4; Valine; Valsartan | 2014 |
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, High-Fat; Fibrosis; Male; Rats, Wistar; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Streptozocin; Thrombospondin 1; Time Factors; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2015 |
Elevated expression of periostin in diabetic cardiomyopathy and the effect of valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Adhesion Molecules; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gene Expression Regulation; Male; Rats; Rats, Wistar; Treatment Outcome; Valsartan | 2015 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Diabetes Mellitus, Experimental; Drug Combinations; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocardium; Neprilysin; RNA, Messenger; Stroke Volume; Tetrazoles; Transforming Growth Factor beta; Valsartan | 2016 |
Valsartan ameliorates podocyte loss in diabetic mice through the Notch pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Immunohistochemistry; Kidney Glomerulus; Male; Mice; Podocytes; Proto-Oncogene Proteins c-bcl-2; Receptors, Notch; Signal Transduction; Tumor Suppressor Protein p53; Valsartan | 2016 |
Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Neprilysin; Rats; Rats, Sprague-Dawley; Streptozocin; Tetrazoles; Valsartan | 2016 |
[Effects of valsartan on the renal vascular endothelial growth factor and its receptor flk-1 of diabetic rats].
Topics: Animals; Antihypertensive Agents; Blotting, Western; Diabetes Mellitus, Experimental; Immunohistochemistry; Kidney; Male; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
[Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Immunosuppressive Agents; Kidney; Male; Mycophenolic Acid; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Tetrazoles; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Valine; Valsartan | 2008 |
Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Kidney; Male; Microdialysis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2008 |
Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomyopathies; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Female; Isoenzymes; L-Lactate Dehydrogenase; Male; Microscopy, Electron; Myocardium; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
[The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathies; Connective Tissue; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2009 |
Effect of renin angiotensin system blockade on the islet microvessel density of diabetic rats and its relationship with islet function.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; Microvessels; Perindopril; Random Allocation; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2009 |
Effects of renin-angiotensin system blockade on islet function in diabetic rats.
Topics: Angiotensinogen; Animals; Apoptosis; Diabetes Mellitus, Experimental; Glucose Tolerance Test; In Situ Nick-End Labeling; Islets of Langerhans; Male; Nitric Oxide Synthase Type II; Perindopril; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2010 |
Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calpain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Kidney Glomerulus; Male; NF-kappa B; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Streptozocin; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2010 |
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan | 2011 |
Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Endoplasmic Reticulum; Fluorescent Antibody Technique; Male; Myocardium; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction; Tetrazoles; Transcription Factor CHOP; Valine; Valsartan; Ventricular Remodeling | 2011 |
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Topics: Administration, Oral; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fumarates; Hemodynamics; Immunoblotting; Male; Mice; Mice, Inbred Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin-1; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Streptozocin; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2012 |
Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Glial Fibrillary Acidic Protein; Hypertension; Metoprolol; Nerve Fibers; Neuroglia; Rats; Rats, Inbred WKY; Renin-Angiotensin System; Retina; Tetrazoles; Valine; Valsartan | 2012 |
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Imidazoles; Liver Cirrhosis; Losartan; Male; Microscopy, Electron; Rats; Tetrazoles; Valine; Valsartan | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Diabetes Mellitus, Experimental; Fumarates; Heart; Humans; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Stress; Prorenin Receptor; Receptors, Cell Surface; Renin; Tetrazoles; Valine; Valsartan | 2013 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil | 2003 |
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Captopril; Cardiomegaly; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension; Hypertrophy; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperglycemia; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nicorandil; Nifedipine; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar; RNA, Messenger; Saralasin; Tetrazoles; Valine; Valsartan | 2003 |
The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Space; Hypertension, Renal; Kidney; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2003 |
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Fluid; Kidney; Losartan; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Mice; Random Allocation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2004 |
Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats.
Topics: Animals; Chemokine CCL2; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Kidney; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2005 |
Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Extracellular Fluid; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Thromboxane B2; Valine; Valsartan | 2005 |
Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.
Topics: Adrenalectomy; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Insulin; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sodium Chloride; Steroid Hydroxylases; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2005 |
[Effect of valsartan on Tribble 3 gene expression in rats with experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathy, Dilated; Diabetes Mellitus, Experimental; Gene Expression; Male; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2006 |
[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Experimental; Fibrosis; Heart; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Thrombospondin 1; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Topics: Adrenal Medulla; Adrenalectomy; Angiotensin II Type 1 Receptor Blockers; Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Gene Expression Regulation; Glucose Transporter Type 4; Glutathione Peroxidase; Liver; Male; Mice; Mice, Knockout; Muscle, Skeletal; Rats; Rats, Wistar; Receptors, Opioid, mu; RNA, Messenger; Streptozocin; Tetrazoles; Tissue Culture Techniques; Valine; Valsartan | 2007 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; Female; Hypertension; Neuroglia; Photic Stimulation; Rats; Retina; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atenolol; Blood Pressure; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Female; Glycated Hemoglobin; Rats; Rats, Sprague-Dawley; Renin; Retinal Vessels; Tetrazoles; Valine; Valsartan | 2007 |
[Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blotting, Western; Cardiomyopathies; Cholesterol; Diabetes Mellitus, Experimental; Fasting; Insulin; Male; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta1; Triglycerides; Valine; Valsartan | 2007 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |
Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Experimental; Hypertension; Male; Metoprolol; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Streptozocin; Tetrazoles; Valine; Valsartan | 2007 |
Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Imidazoles; Immunohistochemistry; Kidney Glomerulus; Kidney Tubules; NADPH Oxidases; Onium Compounds; Prorenin Receptor; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Up-Regulation; Valine; Valsartan | 2008 |
Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Line; Diabetes Mellitus, Experimental; Extracellular Signal-Regulated MAP Kinases; Immunoblotting; Mice; Mice, Inbred C57BL; Neurons; Oncogene Protein v-akt; Phosphorylation; Receptor, Angiotensin, Type 1; Retina; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Synaptophysin; Telmisartan; Tetrazoles; Ubiquitination; Valine; Valsartan | 2008 |
Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Diabetes Mellitus, Experimental; Glomerular Filtration Rate; Hemodynamics; Kinins; Male; Ramipril; Rats; Rats, Sprague-Dawley; Renal Circulation; Tetrazoles; Time Factors; Valine; Valsartan | 1995 |
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Capillary Permeability; Cardiomegaly; Coloring Agents; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Evans Blue; Hypertension; Hypertrophy; Kidney; Male; Mesenteric Arteries; Ramipril; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Serum Albumin; Tetrazoles; Valine; Valsartan | 1996 |
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 1997 |
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Heterozygote; Kidney; Perindopril; Rats; Renin; Tetrazoles; Valine; Valsartan | 2001 |
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Humans; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2001 |
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
[Renal protective effect of valsartan in diabetic rats].
Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibronectins; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 1999 |
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |